PL3183260T3 - Modyfikowane oligonukleotydy i sposoby ich syntezy - Google Patents

Modyfikowane oligonukleotydy i sposoby ich syntezy

Info

Publication number
PL3183260T3
PL3183260T3 PL14838930T PL14838930T PL3183260T3 PL 3183260 T3 PL3183260 T3 PL 3183260T3 PL 14838930 T PL14838930 T PL 14838930T PL 14838930 T PL14838930 T PL 14838930T PL 3183260 T3 PL3183260 T3 PL 3183260T3
Authority
PL
Poland
Prior art keywords
synthesis
methods
modified oligonucleotides
oligonucleotides
modified
Prior art date
Application number
PL14838930T
Other languages
English (en)
Inventor
Dmitry Stetsenko
Maxim KUPRYUSHKIN
Dmitrii PYSHNYI
Original Assignee
Noogen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noogen Llc filed Critical Noogen Llc
Publication of PL3183260T3 publication Critical patent/PL3183260T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL14838930T 2014-08-22 2014-08-28 Modyfikowane oligonukleotydy i sposoby ich syntezy PL3183260T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2014134380A RU2708237C2 (ru) 2014-08-22 2014-08-22 Модифицированные олигонуклеотиды и способ их получения
PCT/RU2014/000647 WO2016028187A1 (en) 2014-08-22 2014-08-28 Modified oligonucleotides and methods for their synthesis
EP14838930.7A EP3183260B1 (en) 2014-08-22 2014-08-28 Modified oligonucleotides and methods for their synthesis

Publications (1)

Publication Number Publication Date
PL3183260T3 true PL3183260T3 (pl) 2021-11-08

Family

ID=52589739

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14838930T PL3183260T3 (pl) 2014-08-22 2014-08-28 Modyfikowane oligonukleotydy i sposoby ich syntezy

Country Status (11)

Country Link
US (2) US11208430B2 (pl)
EP (2) EP3183260B1 (pl)
JP (1) JP6632605B2 (pl)
KR (1) KR102143384B1 (pl)
CN (2) CN115010780A (pl)
DK (1) DK3183260T3 (pl)
ES (1) ES2877560T3 (pl)
PL (1) PL3183260T3 (pl)
PT (1) PT3183260T (pl)
RU (1) RU2708237C2 (pl)
WO (1) WO2016028187A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3452596A4 (en) * 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
AU2017291960B2 (en) 2016-07-05 2024-03-14 Biomarin Technologies B.V. Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
RU2016138168A (ru) * 2016-09-26 2018-03-29 Оксфордский Университет Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
BR112019005928B1 (pt) 2016-09-30 2022-12-20 Dow Global Technologies Llc Composto de fosfaguananidina, complexo de metal-ligante, composto de bifenil- fosfagananidina, catalisador de polimerização, composto de naftaleno de fosfaguananidina e catalisador de polimerização
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
RU2698134C2 (ru) * 2017-12-04 2019-08-22 Общество с ограниченной ответственностью "Биолабмикс" Способ амплификации нуклеиновых кислот с использованием фосфорилгуанидиновых олигонуклеотидов
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP2021521140A (ja) * 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098623A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
CA3098624A1 (en) * 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019392928A1 (en) * 2018-12-06 2021-06-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
EP3917497A4 (en) * 2019-02-01 2023-06-07 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
EP3958872A4 (en) * 2019-04-25 2024-07-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
GB201911403D0 (en) 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CA3156176A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN110627679A (zh) * 2019-10-15 2019-12-31 安徽昊帆生物有限公司 有机叠氮类离子型化合物及其制备方法
RU2738093C9 (ru) * 2019-12-23 2020-12-29 Общество с ограниченной ответственностью "Гелеспон" Способ синтеза 2'-о-(2-метоксиэтил) тиофосфатного олигонуклеотида
AU2021230473A1 (en) * 2020-03-01 2022-09-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
AU2021277407A1 (en) * 2020-05-22 2022-11-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2022081046A1 (ru) * 2020-10-12 2022-04-21 Максим Сергеевич КУПРЮШКИН Химическое соединение с триазиновой группой и способ его получения
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2023285700A1 (en) 2021-07-16 2023-01-19 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide for inhibiting quaking activity
GB202205213D0 (en) 2022-04-08 2022-05-25 Univ Oxford Innovation Ltd Lysine rich cell-penetrating peptides
UY40258A (es) 2022-05-06 2023-11-15 Academisch Ziekenhuis Leiden Oligonucleótido
JP2025527208A (ja) 2022-07-25 2025-08-20 ヴィコ・セラピューティクス・ベー・フェー Appの異常なプロセシングに関連する疾患又は病態の治療用アンチセンスオリゴヌクレオチド
GB202216207D0 (en) 2022-11-01 2022-12-14 Univ Oxford Innovation Ltd Shortened cell-penetrating peptides
WO2024231752A1 (en) 2023-05-10 2024-11-14 Solventum Intellectual Properties Company Process for producing a zirconia dental article
AU2024348221A1 (en) 2023-09-27 2026-04-30 Judo Bio Inc. Aminoglycosides for delivery of agents to the kidney
EP4784753A2 (en) 2023-09-27 2026-08-05 Judo Bio Inc. Slc6a19-targeting modulatory nucleic acid agents
EP4784172A1 (en) 2023-09-27 2026-08-05 Judo Bio Inc. Polymyxins for delivery of agents to the kidney
GB202405980D0 (en) 2024-04-29 2024-06-12 Univ Oxford Innovation Ltd Conjugate for treating repeat expansion disorders
US20250388619A1 (en) * 2024-05-10 2025-12-25 Bio-Synthesis, Inc. Versatile synthetic route for neutral morpholino oligonucleotides with phosphoryl guanidinium (pg) backbone
WO2026080323A1 (en) 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts
WO2026099473A1 (en) * 2024-11-08 2026-05-15 Vico Therapeutics B.V. Oligonucleotides with new internucleoside linkage

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634555A (en) * 1969-07-31 1972-01-11 Du Pont Phosphorylguanidine esters
FR2092794B1 (pl) * 1970-06-19 1974-03-22 Ugine Kuhlmann
US4154826A (en) * 1976-12-30 1979-05-15 Ciba-Geigy Corporation Thiophosphorylguanidines for combating pests
EP0406309A4 (en) * 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
EP1207909A2 (en) 1999-08-27 2002-05-29 Medical Research Council Method for coupling molecules
AU2002317087A1 (en) * 2001-06-29 2003-03-03 Micrologix Biotech Inc. Phosphoramide containing nucleic acid-based compounds and libraries as antivirals
WO2006023880A2 (en) 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
ES2332139T3 (es) * 2005-11-23 2010-01-27 F. Hoffmann-La Roche Ag Polinucleotidos con mimetico de fosfato.
EP2147010A1 (en) * 2007-04-18 2010-01-27 Roche Diagnostics GmbH Nucleotide with an alpha-phosphate mimetic
WO2008141799A1 (en) 2007-05-24 2008-11-27 Roche Diagnostics Gmbh Oligophosphoramidates
US9290534B2 (en) * 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
WO2009147368A1 (en) 2008-06-04 2009-12-10 Medical Research Council Peptides
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
RU2016138168A (ru) 2016-09-26 2018-03-29 Оксфордский Университет Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
RU2740501C2 (ru) 2017-02-21 2021-01-14 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
RU2698134C2 (ru) 2017-12-04 2019-08-22 Общество с ограниченной ответственностью "Биолабмикс" Способ амплификации нуклеиновых кислот с использованием фосфорилгуанидиновых олигонуклеотидов
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2019392928A1 (en) 2018-12-06 2021-06-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US11686884B2 (en) 2018-12-07 2023-06-27 Apple Inc. Light-absorbing flange lenses
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation

Also Published As

Publication number Publication date
US12415828B2 (en) 2025-09-16
PT3183260T (pt) 2021-07-05
RU2014134380A (ru) 2016-03-20
US20210032283A1 (en) 2021-02-04
WO2016028187A1 (en) 2016-02-25
EP3183260A1 (en) 2017-06-28
DK3183260T3 (da) 2021-06-21
US11208430B2 (en) 2021-12-28
CN106795197A (zh) 2017-05-31
RU2708237C2 (ru) 2019-12-05
CN115010780A (zh) 2022-09-06
JP6632605B2 (ja) 2020-01-22
US20170362270A1 (en) 2017-12-21
KR20170043543A (ko) 2017-04-21
CN106795197B (zh) 2022-06-28
JP2017527277A (ja) 2017-09-21
ES2877560T3 (es) 2021-11-17
EP3183260B1 (en) 2021-03-31
EP3904364A1 (en) 2021-11-03
KR102143384B1 (ko) 2020-08-12

Similar Documents

Publication Publication Date Title
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
IL254039A0 (en) Anti-pvrig antibodies and methods of use
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK3183260T3 (da) Modificerede oligonukleotider og fremgangsmåder til deres syntese
IL251505A0 (en) Neuroactive compounds and methods of use thereof
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
PL3212225T3 (pl) Sposoby i kompozycje zmodyfikowanych limfocytów t
IL272851A (en) Methods of using dipivefrin
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3132009T3 (da) Fremgangsmåde
IL243728A0 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
BR112016024803A2 (pt) suportes abrasivos e métodos de sua formação
HRP20181441T1 (hr) Inhibitori sintaze aldosterona
DK3283210T3 (da) Fremgangsmåde
DK3137873T3 (da) Viscometer and methods of use thereof
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
LT3212237T (lt) Metotreksato vaistinė forma